What LamKap Bio does

LamKap Bio is a privately held Swiss biotechnology company, established in 2019 and headquartered in Pfäffikon (Schwyz), Switzerland, that develops fully human bispecific antibodies for the treatment of malignant solid tumors. The group operates through three wholly-owned subsidiaries — LamKap Bio alpha AG (T cell bispecifics), LamKap Bio beta AG (CD47 / phagocyte engagers), and LamKap Bio gamma AG (GPC3 liver cancer programs) — each developing distinct κλ body molecules against specific tumor-associated antigens, with the target patient population being patients with solid tumors expressing CEACAM5 or GPC3.

The company's core technology is the κλ Body platform licensed from Light Chain Bioscience (NovImmune SA), which produces bispecific antibodies composed of two identical heavy chains paired with one kappa (κ) and one lambda (λ) light chain, retaining natural human antibody architecture and minimizing immunogenicity risk. The lead assets are NILK-2301 (CEAxCD3 T cell engager, in Phase I as of April 2024) and NILK-2401 (CEAxCD47 selective CD47 blocker with active Fc enabling ADCC/ADCP, with CTA filed in Q1 2024); preclinical/discovery programs include NILK-3301 (CEAxCD28 costimulator), NILK-2501 (GPC3xCD3), and NILK-3801 (GPC3xCD28). Manufacturing is handled through a Lonza partnership spanning Slough (UK), Hayward (US), and Basel (Switzerland).

LamKap Bio is a pre-commercial, pre-revenue biotech; the stated revenue model is future biopharmaceutical development and licensing/royalty income upon regulatory approval and commercialization of pipeline assets. The go-to-market is enterprise-oriented, relying on strategic development and licensing partnerships (Light Chain Bioscience for technology, Lonza for CMC), academic and clinical collaborations (VHIO, START Madrid for trial execution), and scientific visibility through peer-reviewed publications and conference presentations (AACR, ESMO, SITC). The leadership team — co-founder and Chairman Dr. Erich Hunziker (former Roche CFO) and COO/CFO Oliver Eckelmann (ex-Roche, Booz, Roland Berger) — underwrites the development strategy; no institutional investors or funding rounds were disclosed in the source data.

Name

LamKap Bio

Legal name

LamKap Bio Group

Website

https://lamkapbio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

LamKap Bio is a privately held Swiss biotech developing fully human bispecific κλ (kappa-lambda) antibodies for treating solid tumors, including lead asset NILK-2301 (CEAxCD3) in Phase I and NILK-2401 (CD47/CEACAM5) under CTA review.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals (Bispecific Antibody Therapeutics)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

akta.pro secondary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

Keywords

• Bispecific antibody therapeutics
• Cancer immunotherapy
• Oncology biopharmaceuticals
• Antibody drug development
• Immuno-oncology research

Headquarters

HQ city

Pfaffikon

HQ country

Switzerland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Biopharmaceutical Development and Licensing: LamKap Bio is a pre-commercial biotechnology company focused on developing bispecific antibody therapeutics. Revenue will be generated through clinical development, regulatory approvals, and potential licensing or commercialization of therapeutic products. The company operates through three subsidiaries (alpha, beta, gamma) each dedicated to different bsAb projects targeting specific tumor-associated antigens.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

LamKap Bio researches, develops, and manufactures bispecific antibodies for the treatment of malignant solid tumors. The company uses fully human κλ (kappa-lambda) antibody formats to redirect patients' own immune cells — macrophages, T-cells, and natural killer cells — to selectively attack cancer cells expressing tumor-associated antigens such as CEACAM5 (CEA) and GPC3. Pipeline products target combinations of CD3, CD28, and CD47 with tumor antigens.

Product overview

LamKap Bio is a biotechnology group comprising three subsidiaries (LamKap Bio alpha AG, LamKap Bio beta AG, and LamKap Bio gamma AG), each dedicated to developing tumor-targeted bispecific antibody therapies. The company leverages the proprietary κλ Body platform (developed by partner LightChain Bioscience) to create fully human bispecific antibodies. The pipeline includes five molecules: NILK-2301 (CEA x CD3, Phase I), NILK-2401 (CEA x CD47, CTA filed), NILK-3301 (CEA x CD28, preclinical), NILK-2501 (GPC3 x CD3, discovery), and NILK-3801 (GPC3 x CD28, discovery). The products retarget immune cells (T cells, macrophages, NK cells) to attack cancer cells, helping the body fight cancer.

Differentiator

Problem solved

Functional benefit

Brands

• LamKap Bio alpha: Subsidiary focused on development of T cell bispecific antibodies (TCBs) targeting CEA (CEACAM5) and CD3/CD28.
• LamKap Bio beta
• LamKap Bio gamma
• NILK-2301
• NILK-2401
• NILK-3301
• NILK-2501
• NILK-3801

Products and services

• NILK-2301 A CEA (CEACAM5) x CD3 bispecific κλ body antibody that drives T-cell retargeting to tumor cells by pairing a high-affinity anti-CEA arm to an optimized low-affinity anti-CD3 arm. Currently in Phase I (first patient dosed April 2024). Target: solid tumors expressing CEACAM5.
• NILK-3301 A CEA (CEACAM5) x CD28 bispecific κλ body antibody that provides costimulatory signal to T cells via co-engagement of CEA. Used to enhance anti-tumor efficacy driven by T-cell retargeting bispecific antibodies or to synergize with checkpoint inhibitors. Currently in preclinical development.
• NILK-2401 A CEA (CEACAM5) x CD47 bispecific κλ body antibody that drives selective CD47 blockade to tumor cells expressing CEACAM5. Contains a fully competent IgG1 Fc-domain allowing ADCC and ADCP effector functions. CTA filed in Q1/2024.
• NILK-2501 A GPC3 x CD3 bispecific κλ body antibody that drives T-cell retargeting to tumor cells by pairing a high-affinity anti-GPC3 arm to an optimized low-affinity anti-CD3 arm. Currently in discovery phase. Indications focus on liver cancer (hepatocellular carcinoma) treatment.
• NILK-3801 A GPC3 x CD28 bispecific κλ body antibody that provides costimulatory signal to T cells via co-engagement of GPC3. Used to enhance anti-tumor efficacy or synergize with checkpoint inhibitors. Currently in discovery phase. Indication: liver cancer.

Quantifiable outcome

• EngMab (BCMAxCD3 bsAb) acquired by Celgene in 2016; first clinical results presented at ASH 2019
• +2 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• LonzacoreStrategic or Co-development Partner · 17 September 2020Lonza and LamKap Bio Group entered a development and manufacturing collaboration for bispecific antibody products. Lonza provides cell line and process development, drug substance manufacturing, and drug product services for NILK-2301 and NILK-2401. Lonza's LightPath cell line development program based on GS Gene Expression System supports Phase I clinical studies. Manufacturing conducted at Slough UK, Hayward US, and Basel Switzerland sites.
• Light Chain Bioscience / NovImmune SAcoreTechnology or IntegrationLight Chain Bioscience (NovImmune SA) is LamKap Bio's strategic technology partner providing the proprietary κλ body bispecific antibody platform. The partnership enables development of fully human bispecific antibodies targeting tumor cells. Light Chain Bioscience serves as clinical development sponsor for NILK-2401 and collaborates with LamKap Bio on multiple pipeline programs.
• Val d'Hebron Institute of Oncology (VHIO)coreStrategic or Co-development PartnerVHIO is a clinical trial partner for the Phase I study of NILK-2301, a CEACAM5xCD3 bispecific antibody for solid cancers. The collaboration is led by Prof Josep Tabernero and focuses on early clinical development and immunotherapy of cancer.
• START Madrid – FJDcoreStrategic or Co-development PartnerSTART Madrid (Fundación Jiménez Díaz) is a clinical trial partner for the Phase I study of NILK-2301, providing clinical development expertise in immunotherapy of cancer. Led by Victor Moreno, the institution contributes experience in early clinical development of novel cancer therapies.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Xencor: Clinical-stage biotech with XmAb bispecific and XmAb 2+1 T-cell engager platforms, multiple oncology bispecifics in trials — directly comparable modality and stage.
• Genmab: Pioneer in bispecific antibody technology (Duobody platform) with multiple clinical-stage oncology bispecifics including T-cell engagers — the most direct established competitor to LamKap's bispecific approach.
• Macrogenics: Clinical-stage biotech developing DART and TRIDENT bispecific antibodies for cancer, with multiple programs targeting tumor-associated antigens — closely comparable to LamKap's CEA- and GPC3-directed molecules.
• Zymeworks: Developer of multiple bispecific antibody platforms (Azymetric, ZymeLinker) with clinical-stage oncology candidates targeting solid tumors, directly comparable format and indication overlap with LamKap.
• Numab Therapeutics: Swiss-based biotech developing multi-specific antibodies using a proprietary κλ-body–equivalent fully human format most comparable to LamKap's platform. Targets oncology and inflammation, similar indications and engineering philosophy.
• ABL Bio: South Korea-based biotech developing bispecific antibodies for oncology including T-cell engagers and immune-cell redirectors, with phase assets for solid tumors analogous to LamKap's NILK program.
• Harpoon Therapeutics (acquired by Merck): Developed TriTAC T-cell engagers for solid-tumor indications including those targeting tumor-associated antigens — closest functional analog to LamKap's TCB programs and was acquired by Merck in 2024 for similar strategic reasons.

Broad incumbents

• Roche: Global oncology leader with multiple bispecific antibodies (e.g., Hemlibra, Tecentriq combinations) and deep interest in CEA/CD3 and CD47 biology; large-cap incumbent whose roadmap constrains pricing power for niche bispecific developers.
• NovImmune / Light Chain Bioscience: LamKap's licensor and technology partner — owner of the κλ-body platform and developer of multiple bispecifics including NILK-2401 (as clinical sponsor). Comparable as the upstream platform company and natural M&A target.

Emerging players

• Inhibrx (acquired by Sanofi): Clinical-stage bispecific developer with sdAb-based platforms targeting cancer; comparable modality and was acquired by Sanofi in 2024, similar trajectory to EngMab precedent relevant to LamKap.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/lamkap-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LamKap Bio